iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing Jun 23, 2025 04:06PM
Needham Reiterates Buy Rating on OncoCyte Corp (OCX) May 13, 2025 06:44AM
OncoCyte (OCX) Provides Positive Update on Clinical Trial Progress Apr 30, 2025 08:31AM
OncoCyte's (OCX) Proprietary Assay Demonstrates Long-Term Clinical Validity Apr 29, 2025 08:34AM
OncoCyte (OCX) Files for 10.61M Share Offering by Selling Stockholders Mar 31, 2025 01:32PM


Mar 31, 2025 01:30PM OncoCyte (OCX) Files for 10.61M Share Offering by Selling Stockholders
Mar 28, 2025 09:00AM Lake Street Capital Markets Starts OncoCyte Corp (OCX) at Buy
Mar 25, 2025 06:29AM Needham Reiterates Buy Rating on OncoCyte Corp (OCX)
Mar 24, 2025 04:14PM OncoCyte (OCX) Misses Q4 EPS by 193c
Mar 24, 2025 04:06PM OncoCyte (OCX) Reports Successful 2024; Sets Stage for 2025 Catalysts
Feb 10, 2025 08:31AM OncoCyte (OCX) prices $29.1 million equity offering at $2.05 per share
Jan 8, 2025 08:32AM OncoCyte (OCX) Appoints Paul Billings as Consulting Chief Medical Officer
Jan 6, 2025 04:06PM OncoCyte (OCX) Expands Market Opportunity for VitaGraft Kidney
Dec 4, 2024 04:17PM OncoCyte (OCX) Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
Nov 13, 2024 06:34AM Needham Reiterates Buy Rating on OncoCyte Corp (OCX)
Nov 12, 2024 10:45PM OncoCyte (OCX) Misses Q3 EPS by 98c
Oct 16, 2024 05:19PM OncoCyte (OCX) Files for 3.46M Share Offering by Selling Stockholders
Oct 15, 2024 06:11AM Needham Reiterates Buy Rating on OncoCyte Corp (OCX)
Oct 8, 2024 08:32AM OncoCyte's (OCX) DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Oct 3, 2024 06:04AM OncoCyte (OCX) Announces 3.46M Share Offering at $2.95/sh
Oct 3, 2024 06:04AM OncoCyte (OCX) Signs Leading Transplant Centers in US and Germany
Aug 8, 2024 05:14PM OncoCyte (OCX) Misses Q2 EPS by 36c
Jun 17, 2024 04:05PM OncoCyte (OCX) Appoints Andrea James as Chief Financial Officer